On Friday, Travere Therapeutics Inc (NASDAQ: TVTX) was 0.59% up from the session before settling in for the closing price of $18.70. A 52-week range for TVTX has been $5.12 – $20.33.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 3.07% over the past five years. When this article was written, the company’s average yearly earnings per share was at -162.28%. With a float of $85.72 million, this company’s outstanding shares have now reached $87.03 million.
Let’s look at the performance matrix of the company that is accounted for 380 employees. In terms of profitability, gross margin is 84.29%, operating margin of -169.03%, and the pretax margin is -171.4%.
Travere Therapeutics Inc (TVTX) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Travere Therapeutics Inc stocks. The insider ownership of Travere Therapeutics Inc is 1.51%, while institutional ownership is 97.29%. The most recent insider transaction that took place on Nov 25 ’24, was worth 221,258. In this transaction SVP, CHIEF ACCOUNTING OFFICER of this company sold 12,090 shares at a rate of $18.30, taking the stock ownership to the 54,927 shares. Before that another transaction happened on Nov 25 ’24, when Company’s Officer proposed sale 12,090 for $18.30, making the entire transaction worth $221,258.
Travere Therapeutics Inc (TVTX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -162.28% per share during the next fiscal year.
Travere Therapeutics Inc (NASDAQ: TVTX) Trading Performance Indicators
You can see what Travere Therapeutics Inc (TVTX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.68. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.09.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.56, a number that is poised to hit -0.64 in the next quarter and is forecasted to reach -1.19 in one year’s time.
Technical Analysis of Travere Therapeutics Inc (TVTX)
Travere Therapeutics Inc (NASDAQ: TVTX) saw its 5-day average volume 1.25 million, a negative change from its year-to-date volume of 1.4 million. As of the previous 9 days, the stock’s Stochastic %D was 79.18%. Additionally, its Average True Range was 0.93.
During the past 100 days, Travere Therapeutics Inc’s (TVTX) raw stochastic average was set at 87.74%, which indicates a significant increase from 56.20% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 37.49% in the past 14 days, which was lower than the 62.15% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.11, while its 200-day Moving Average is $10.42. Nevertheless, the first resistance level for the watch stands at $19.07 in the near term. At $19.34, the stock is likely to face the second major resistance level. The third major resistance level sits at $19.54. If the price goes on to break the first support level at $18.60, it is likely to go to the next support level at $18.40. The third support level lies at $18.13 if the price breaches the second support level.
Travere Therapeutics Inc (NASDAQ: TVTX) Key Stats
There are 78,050K outstanding shares of the company, which has a market capitalization of 1.65 billion. As of now, sales total 145,240 K while income totals -111,400 K. Its latest quarter income was 62,900 K while its last quarter net income were -54,810 K.
